Global Cancer Biologics Market 2024-2028

Description

List of Tables

The cancer biologics market is forecasted to grow by USD 51.08 bn during 2023-2028, accelerating at a CAGR of 9.18% during the forecast period. The report on the cancer biologics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the rising global incidence of cancer, increased demand for cancer biologics due to emphasis on personalized medicines, and significant therapeutic benefits of cancer biologics.

Technavio's cancer biologics market is segmented as below:

Market Scope
Base Year	2024
End Year	2028
Series Year	2024-2028
Growth Momentum	Accelerate
YOY 2024	8.16%
CAGR	9.18%
Incremental Value	$51.08bn

By Product

Monoclonal antibodies
Cell and gene therapy
Vaccines
Others

By Route Of Administration

Injectable
Oral

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the untapped potential of cancer biologics in developing countries as one of the prime reasons driving the cancer biologics market growth during the next few years. Also, a rise in R&D for the development of innovative cancer biologics and increased use of predictive biomarkers will lead to sizable demand in the market.

The report on the cancer biologics market covers the following areas:

Cancer biologics market sizing
Cancer biologics market forecast
Cancer biologics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading cancer biologics market vendors that include Amgen Inc., AstraZeneca Plc, Bayer AG, Biocon Ltd., Biogen Inc., Bristol Myers Squibb Co., Celltrion Co. Ltd., Cipla Ltd., Dr Reddys Laboratories Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Jazz Pharmaceuticals Plc, Johnson and Johnson, Lupin Ltd., Merck KGaA, Novartis AG, Ono Pharmaceutical Co. Ltd., and Viatris Inc.. Also, the cancer biologics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources through an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Product Code: IRTNTR72894

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Product
Exhibit 06: Executive Summary - Chart on Market Segmentation by Route of Administration
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion)
Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global cancer biologics market 2018 - 2022
Exhibit 18: Historic Market Size - Data Table on global cancer biologics market 2018 - 2022 ($ billion)
4.2 Product Segment Analysis 2018 - 2022
Exhibit 19: Historic Market Size - Product Segment 2018 - 2022 ($ billion)
4.3 Route of administration Segment Analysis 2018 - 2022
Exhibit 20: Historic Market Size - Route of administration Segment 2018 - 2022 ($ billion)
4.4 Geography Segment Analysis 2018 - 2022
Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion)
4.5 Country Segment Analysis 2018 - 2022
Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Product

6.1 Market segments
Exhibit 30: Chart on Product - Market share 2023-2028 (%)
Exhibit 31: Data Table on Product - Market share 2023-2028 (%)
6.2 Comparison by Product
Exhibit 32: Chart on Comparison by Product
Exhibit 33: Data Table on Comparison by Product
6.3 Monoclonal antibodies - Market size and forecast 2023-2028
Exhibit 34: Chart on Monoclonal antibodies - Market size and forecast 2023-2028 ($ billion)
Exhibit 35: Data Table on Monoclonal antibodies - Market size and forecast 2023-2028 ($ billion)
Exhibit 36: Chart on Monoclonal antibodies - Year-over-year growth 2023-2028 (%)
Exhibit 37: Data Table on Monoclonal antibodies - Year-over-year growth 2023-2028 (%)
6.4 Cell and gene therapy - Market size and forecast 2023-2028
Exhibit 38: Chart on Cell and gene therapy - Market size and forecast 2023-2028 ($ billion)
Exhibit 39: Data Table on Cell and gene therapy - Market size and forecast 2023-2028 ($ billion)
Exhibit 40: Chart on Cell and gene therapy - Year-over-year growth 2023-2028 (%)
Exhibit 41: Data Table on Cell and gene therapy - Year-over-year growth 2023-2028 (%)
6.5 Vaccines - Market size and forecast 2023-2028
Exhibit 42: Chart on Vaccines - Market size and forecast 2023-2028 ($ billion)
Exhibit 43: Data Table on Vaccines - Market size and forecast 2023-2028 ($ billion)
Exhibit 44: Chart on Vaccines - Year-over-year growth 2023-2028 (%)
Exhibit 45: Data Table on Vaccines - Year-over-year growth 2023-2028 (%)
6.6 Others - Market size and forecast 2023-2028
Exhibit 46: Chart on Others - Market size and forecast 2023-2028 ($ billion)
Exhibit 47: Data Table on Others - Market size and forecast 2023-2028 ($ billion)
Exhibit 48: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibit 49: Data Table on Others - Year-over-year growth 2023-2028 (%)
6.7 Market opportunity by Product
Exhibit 50: Market opportunity by Product ($ billion)
Exhibit 51: Data Table on Market opportunity by Product ($ billion)

7 Market Segmentation by Route of Administration

7.1 Market segments
Exhibit 52: Chart on Route of Administration - Market share 2023-2028 (%)
Exhibit 53: Data Table on Route of Administration - Market share 2023-2028 (%)
7.2 Comparison by Route of Administration
Exhibit 54: Chart on Comparison by Route of Administration
Exhibit 55: Data Table on Comparison by Route of Administration
7.3 Injectable - Market size and forecast 2023-2028
Exhibit 56: Chart on Injectable - Market size and forecast 2023-2028 ($ billion)
Exhibit 57: Data Table on Injectable - Market size and forecast 2023-2028 ($ billion)
Exhibit 58: Chart on Injectable - Year-over-year growth 2023-2028 (%)
Exhibit 59: Data Table on Injectable - Year-over-year growth 2023-2028 (%)
7.4 Oral - Market size and forecast 2023-2028
Exhibit 60: Chart on Oral - Market size and forecast 2023-2028 ($ billion)
Exhibit 61: Data Table on Oral - Market size and forecast 2023-2028 ($ billion)
Exhibit 62: Chart on Oral - Year-over-year growth 2023-2028 (%)
Exhibit 63: Data Table on Oral - Year-over-year growth 2023-2028 (%)
7.5 Market opportunity by Route of Administration
Exhibit 64: Market opportunity by Route of Administration ($ billion)
Exhibit 65: Data Table on Market opportunity by Route of Administration ($ billion)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 67: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibit 68: Data Table on Market share By Geographical Landscape 2023-2028 (%)
9.2 Geographic comparison
Exhibit 69: Chart on Geographic comparison
Exhibit 70: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2023-2028
Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ billion)
Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)
9.4 Europe - Market size and forecast 2023-2028
Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ billion)
Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
9.5 Asia - Market size and forecast 2023-2028
Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ billion)
Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
9.6 Rest of World (ROW) - Market size and forecast 2023-2028
Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion)
Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
9.7 US - Market size and forecast 2023-2028
Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ billion)
Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%)
Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%)
9.8 UK - Market size and forecast 2023-2028
Exhibit 91: Chart on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 92: Data Table on UK - Market size and forecast 2023-2028 ($ billion)
Exhibit 93: Chart on UK - Year-over-year growth 2023-2028 (%)
Exhibit 94: Data Table on UK - Year-over-year growth 2023-2028 (%)
9.9 Germany - Market size and forecast 2023-2028
Exhibit 95: Chart on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 96: Data Table on Germany - Market size and forecast 2023-2028 ($ billion)
Exhibit 97: Chart on Germany - Year-over-year growth 2023-2028 (%)
Exhibit 98: Data Table on Germany - Year-over-year growth 2023-2028 (%)
9.10 Canada - Market size and forecast 2023-2028
Exhibit 99: Chart on Canada - Market size and forecast 2023-2028 ($ billion)
Exhibit 100: Data Table on Canada - Market size and forecast 2023-2028 ($ billion)
Exhibit 101: Chart on Canada - Year-over-year growth 2023-2028 (%)
Exhibit 102: Data Table on Canada - Year-over-year growth 2023-2028 (%)
9.11 China - Market size and forecast 2023-2028
Exhibit 103: Chart on China - Market size and forecast 2023-2028 ($ billion)
Exhibit 104: Data Table on China - Market size and forecast 2023-2028 ($ billion)
Exhibit 105: Chart on China - Year-over-year growth 2023-2028 (%)
Exhibit 106: Data Table on China - Year-over-year growth 2023-2028 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 107: Market opportunity By Geographical Landscape ($ billion)
Exhibit 108: Data Tables on Market opportunity By Geographical Landscape ($ billion)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 109: Impact of drivers and challenges in 2023 and 2028
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 111: Overview on factors of disruption
11.4 Industry risks
Exhibit 112: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 113: Vendors covered
12.2 Market positioning of vendors
Exhibit 114: Matrix on vendor position and classification
12.3 Amgen Inc.
Exhibit 115: Amgen Inc. - Overview
Exhibit 116: Amgen Inc. - Product / Service
Exhibit 117: Amgen Inc. - Key offerings
12.4 AstraZeneca Plc
Exhibit 118: AstraZeneca Plc - Overview
Exhibit 119: AstraZeneca Plc - Product / Service
Exhibit 120: AstraZeneca Plc - Key news
Exhibit 121: AstraZeneca Plc - Key offerings
12.5 Bayer AG
Exhibit 122: Bayer AG - Overview
Exhibit 123: Bayer AG - Business segments
Exhibit 124: Bayer AG - Key news
Exhibit 125: Bayer AG - Key offerings
Exhibit 126: Bayer AG - Segment focus
12.6 Biocon Ltd.
Exhibit 127: Biocon Ltd. - Overview
Exhibit 128: Biocon Ltd. - Business segments
Exhibit 129: Biocon Ltd. - Key offerings
Exhibit 130: Biocon Ltd. - Segment focus
12.7 Biogen Inc.
Exhibit 131: Biogen Inc. - Overview
Exhibit 132: Biogen Inc. - Product / Service
Exhibit 133: Biogen Inc. - Key offerings
12.8 Bristol Myers Squibb Co.
Exhibit 134: Bristol Myers Squibb Co. - Overview
Exhibit 135: Bristol Myers Squibb Co. - Product / Service
Exhibit 136: Bristol Myers Squibb Co. - Key news
Exhibit 137: Bristol Myers Squibb Co. - Key offerings
12.9 Celltrion Co. Ltd.
Exhibit 138: Celltrion Co. Ltd. - Overview
Exhibit 139: Celltrion Co. Ltd. - Product / Service
Exhibit 140: Celltrion Co. Ltd. - Key offerings
12.10 Cipla Ltd.
Exhibit 141: Cipla Ltd. - Overview
Exhibit 142: Cipla Ltd. - Business segments
Exhibit 143: Cipla Ltd. - Key news
Exhibit 144: Cipla Ltd. - Key offerings
Exhibit 145: Cipla Ltd. - Segment focus
12.11 Dr Reddys Laboratories Ltd.
Exhibit 146: Dr Reddys Laboratories Ltd. - Overview
Exhibit 147: Dr Reddys Laboratories Ltd. - Business segments
Exhibit 148: Dr Reddys Laboratories Ltd. - Key offerings
Exhibit 149: Dr Reddys Laboratories Ltd. - Segment focus
12.12 Eli Lilly and Co.
Exhibit 150: Eli Lilly and Co. - Overview
Exhibit 151: Eli Lilly and Co. - Product / Service
Exhibit 152: Eli Lilly and Co. - Key news
Exhibit 153: Eli Lilly and Co. - Key offerings
12.13 F. Hoffmann La Roche Ltd.
Exhibit 154: F. Hoffmann La Roche Ltd. - Overview
Exhibit 155: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 156: F. Hoffmann La Roche Ltd. - Key news
Exhibit 157: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 158: F. Hoffmann La Roche Ltd. - Segment focus
12.14 Gilead Sciences Inc.
Exhibit 159: Gilead Sciences Inc. - Overview
Exhibit 160: Gilead Sciences Inc. - Product / Service
Exhibit 161: Gilead Sciences Inc. - Key news
Exhibit 162: Gilead Sciences Inc. - Key offerings
12.15 GlaxoSmithKline Plc
Exhibit 163: GlaxoSmithKline Plc - Overview
Exhibit 164: GlaxoSmithKline Plc - Business segments
Exhibit 165: GlaxoSmithKline Plc - Key news
Exhibit 166: GlaxoSmithKline Plc - Key offerings
Exhibit 167: GlaxoSmithKline Plc - Segment focus
12.16 Jazz Pharmaceuticals Plc
Exhibit 168: Jazz Pharmaceuticals Plc - Overview
Exhibit 169: Jazz Pharmaceuticals Plc - Product / Service
Exhibit 170: Jazz Pharmaceuticals Plc - Key news
Exhibit 171: Jazz Pharmaceuticals Plc - Key offerings
12.17 Merck KGaA
Exhibit 172: Merck KGaA - Overview
Exhibit 173: Merck KGaA - Business segments
Exhibit 174: Merck KGaA - Key news
Exhibit 175: Merck KGaA - Key offerings
Exhibit 176: Merck KGaA - Segment focus

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 177: Inclusions checklist
Exhibit 178: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 179: Currency conversion rates for US$
13.4 Research methodology
Exhibit 180: Research methodology
Exhibit 181: Validation techniques employed for market sizing
Exhibit 182: Information sources
13.5 List of abbreviations
Exhibit 183: List of abbreviations